TipRanks
Advertisement
Advertisement
X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)
PremiumThe FlyX4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)
3M ago
X4’s Mavorixafor Liver Study Completion: What Investors Should Watch Next
Premium
Company Announcements
X4’s Mavorixafor Liver Study Completion: What Investors Should Watch Next
3M ago
X4 Pharmaceuticals initiated with an Overweight at Wells Fargo
Premium
The Fly
X4 Pharmaceuticals initiated with an Overweight at Wells Fargo
3M ago
Six new option listings on May 13th
PremiumThe FlySix new option listings on May 13th
5M ago
X4 Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
Premium
Company Announcements
X4 Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
5M ago
X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)
Premium
The Fly
X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)
6M ago
X4 Pharmaceuticals (XFOR) Q4 Earnings Cheat Sheet
PremiumPre-EarningsX4 Pharmaceuticals (XFOR) Q4 Earnings Cheat Sheet
8M ago
X4 Pharmaceuticals initiated with a Buy at Guggenheim
Premium
The Fly
X4 Pharmaceuticals initiated with a Buy at Guggenheim
8M ago
X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor
Premium
The Fly
X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor
8M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―